The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Open accessAbstract
CRISPR RNA-guided nucleases (RGNs) are widely used genome-editing reagents, but methods to delineate their genome-wide, off-target cleavage activities have been lacking. Here we describe an approach for global detection of DNA double-stranded breaks (DSBs) introduced by RGNs and potentially other nucleases. This method, called genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq), relies on capture of double-stranded oligodeoxynucleotides into DSBs. Application of GUIDE-seq to 13 RGNs in two human cell lines revealed wide variability in RGN off-target activities and unappreciated characteristics of off-target sequences. The majority of identified sites were not detected by existing computational methods or chromatin immunoprecipitation sequencing (ChIP-seq). GUIDE-seq also identified RGN-independent genomic breakpoint 'hotspots'. Finally, GUIDE-seq revealed that truncated guide RNAs exhibit substantially reduced RGN-induced, off-target DSBs. Our experiments define the most rigorous framework for genome-wide identification of RGN off-target effects to date and provide a method for evaluating the safety of these nucleases before clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A primary limitation of GUIDE-seq is relevant to the low delivery efficiency of dsODNs into cells, which results in detection of only 30%–50% of all the DSBs (Tsai et al., 2015; Pan et al., 2022).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Off-target profiling of AsCas12a-crRNA+11 genome editing in HEK293/3272-26A>G cells18,42 showed very high specificity, as demonstrated by exclusive editing of the 3272-26A>G CFTR locus, while non-specific cleavages in the second allele, or any other genomic loci, could not be detected (Fig. 2c and Supplementary Fig. 4c).”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While cleavage at sites with perfect complementarity to the protospacer domain of the gRNA typically occurs with highest efficiency, cleavage at sites having one to several bases of mismatch with the gRNA can occur. These undesired cleavage events are called “off-target effects” (OTEs)10, and their existence should be minimized for therapeutic applications of genome editing technologies.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The GUIDE-seq procedure10 can be used to empirically identify real off-target sites in cells.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq can detect off-target sites with indel frequencies as low as 0.03% (Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq is more sensitive than the IDLV method because dsODNs integrate more efficiently and precisely into DSBs, while the integration events of IDLV is low in number and can distribute as far as 500bp away from the actual DSB sites (Tsai et al., 2015; Cromer et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“However, other publications observed a much lower validation rate (Cencic et al., 2014; Duan et al., 2014; Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“These studies indicated that Cas9 could associate with genomic loci without exerting its nuclease function, deposing a major caveat in Cas9 ChIP-Seq-based off-target detection assay.”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, compared to cell-based methods such as GUIDE-seq (see next section) (Tsai et al., 2015), Extru-seq exhibited much lower false negative rate (2.3% versus 29%) (Kwon et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
In the citing paper
“Using the standard Guide-seq protocol, we detected only the Fah target site and one off-target site (defined as Guide-seq off-target site 1, or GOT1) (Supplementary Data Set 1).”
From Adenine base editing in an adult mouse model of tyrosinaemia (2019) · cites this paper as [23]
In the citing paper
“However, silicon methods can only identify part of the off-target cleavage.48”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [48]
In the citing paper
“The major barrier of clinical use of CRISPR/Cas9 is its off-target effects [81,82,83].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citationCRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Self-citationRNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,009
Expanding C–T base editing toolkit with diversified cytidine deaminases
Cheng, T., Li, S., Yuan, B., Wang, X., Zhou, W., & Qiu, Z. (2019) · Nature Communications · doi:10.1038/s41467-019-11562-6 · Cited by 74
Recent advances in gene therapy for neurodevelopmental disorders with epilepsy
Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15168 · Cited by 71
Genome engineering: a new approach to gene therapy for neuromuscular disorders
Nelson, C. E., Robinson-Hamm, J. N., & Gersbach, C. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.126 · Cited by 73
Panel), E. P. O. G. M. O. (. G., Naegeli, H., Bresson, J., Dalmay, T., Dewhurst, I. C., Epstein, M. M., Firbank, L. G., Guerche, P., Hejátko, J., Moreno, F. J., et al. (2020) · EFSA Journal · doi:10.2903/j.efsa.2020.6299 · Cited by 77
Ling, X., Chang, L., Chen, H., Gao, X., Yin, J., Zuo, Y., Huang, Y., Zhang, B., Hu, J., & Liu, T. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.021 · Cited by 72
Distinct patterns of Cas9 mismatch tolerancein vitroandin vivo
Fu, B. X. H., St.Onge, R. P., Fire, A. Z., & Smith, J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw417 · Cited by 75
Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection
Allen, A. G., Chung, C.-H., Atkins, A., Dampier, W., Khalili, K., Nonnemacher, M. R., & Wigdahl, B. L. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02940 · Cited by 70
Cancellieri, S., Canver, M. C., Bombieri, N., Giugno, R., & Pinello, L. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz867 · Cited by 75
Analysis of NHEJ-Based DNA Repair after CRISPR-Mediated DNA Cleavage
Song, B., Yang, S., Hwang, G., Yu, J., & Bae, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126397 · Cited by 75
Gao, R., Fu, Z.-C., Li, X., Wang, Y., Wei, J., Li, G., Wang, L., Wu, J., Xue, W., Huang, X., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0080 · Cited by 74
Moyo, B., Bloom, K. M., Scott, T. A., Ely, A., & Arbuthnot, P. B. (2017) · Virus Research · doi:10.1016/j.virusres.2017.01.003 · Cited by 70
Critical roles of αII spectrin in brain development and epileptic encephalopathy
Wang, Y., Ji, T., Nelson, A. D., Glanowska, K. M., Murphy, G. G., Jenkins, P. M., & Parent, J. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95743 · Cited by 70
Prediction-based highly sensitive CRISPR off-target validation using target-specific DNA enrichment
Kang, S.-H., Lee, W.-J., An, J.-H., Lee, J., Kim, Y.-H., Kim, H., Oh, Y., Park, Y., Jin, Y. B., Jun, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17418-8 · Cited by 73
Towards a new era in medicine: therapeutic genome editing
Porteus, M. H. (2015) · Genome Biology · doi:10.1186/s13059-015-0859-y · Cited by 69
Donohoue, P. D., Pacesa, M., Lau, E., Vidal, B., Irby, M. J., Nyer, D. B., Rotstein, T., Banh, L., Toh, M. S., Gibson, J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.035 · Cited by 69
Bulcaen, M., Kortleven, P., Liu, R. B., Maule, G., Dreano, E., Kelly, M., Ensinck, M. M., Thierie, S., Smits, M., Ciciani, M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101544 · Cited by 69
Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy
Robinson-Hamm, J. N., & Gersbach, C. A. (2016) · Human Genetics · doi:10.1007/s00439-016-1725-z · Cited by 72
CRISPR/Cas9 gene-editing strategies in cardiovascular cells
Vermersch, E., Jouve, C., & Hulot, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz250 · Cited by 74
Shapiro, J., Iancu, O., Jacobi, A. M., McNeill, M., Turk, R., Rettig, G. R., Amit, I., Tovin, A., Yakhini, Z., Behlke, M. A., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.027 · Cited by 72
CRISPR gRNA phenotypic screening in zebrafish reveals pro-regenerative genes in spinal cord injury
Keatinge, M., Tsarouchas, T. M., Munir, T., Porter, N. J., Larraz, J., Gianni, D., Tsai, H., Becker, C. G., Lyons, D. A., & Becker, T. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009515 · Cited by 69
Kiourtis, C., Wilczynska, A., Nixon, C., Clark, W. A., May, S., & Bird, T. G. (2021) · Biology Open · doi:10.1242/bio.058678 · Cited by 70
Hasanzadeh, A., Hamblin, M. R., Kiani, J., Noori, H., Hardie, J. M., Karimi, M., & Shafiee, H. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101665 · Cited by 73
Izmiryan, A., Ganier, C., Bovolenta, M., Schmitt, A., Mavilio, F., & Hovnanian, A. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.008 · Cited by 68
Fine-Tuning Next-Generation Genome Editing Tools
Kanchiswamy, C. N., Maffei, M. E., Malnoy, M., Velasco, R., & Kim, J. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.03.007 · Cited by 70
Detect-seq reveals out-of-protospacer editing and target-strand editing by cytosine base editors
Lei, Z., Meng, H., Lv, Z., Liu, M., Zhao, H., Wu, H., Zhang, X., Liu, L., Zhuang, Y., Yin, K., et al. (2021) · Nature Methods · doi:10.1038/s41592-021-01172-w · Cited by 67
In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies
Yanik, M., Müller, B., Song, F., Gáll, J., Wagner, F., Wende, W., Lorenz, B., & Stieger, K. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.09.001 · Cited by 73
CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges
Demirci, S., Leonard, A., Haro-Mora, J. J., Uchida, N., & Tisdale, J. F. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2018_331 · Cited by 50
Guidelines for Optimized Gene Knockout Using CRISPR/Cas9
Campenhout, C. V., Cabochette, P., Veillard, A.-C., Laczik, M., Zelisko-Schmidt, A., Sabatel, C., Dhainaut, M., Vanhollebeke, B., Gueydan, C., & Kruys, V. (2019) · BioTechniques · doi:10.2144/btn-2018-0187 · Cited by 73
Evolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 70
A highly efficient transgene knock-in technology in clinically relevant cell types
Allen, A. G., Khan, S., Margulies, C. M., Viswanathan, R., Lele, S. S., Blaha, L. C., Scott, S. N., Izzo, K. M., Gerew, A., Pattali, R. K., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01779-8 · Cited by 71
Designed nucleases for targeted genome editing
Lee, J., Chung, J., Kim, H. M., Kim, S., & Kim, S. (2015) · Plant Biotechnology Journal · doi:10.1111/pbi.12465 · Cited by 70
Expression of CRISPR/Cas single guide RNAs using small tRNA promoters
Mefferd, A. L., Kornepati, A. V. R., Bogerd, H. P., Kennedy, E. M., & Cullen, B. R. (2015) · RNA · doi:10.1261/rna.051631.115 · Cited by 70
Yin, C., Zhang, T., Li, F., Yang, F., Putatunda, R., Young, W., Khalili, K., Hu, W., & Zhang, Y. (2016) · AIDS · doi:10.1097/qad.0000000000001079 · Cited by 67
Ethical and regulatory aspects of genome editing
Kohn, D. B., Porteus, M. H., & Scharenberg, A. M. (2016) · Blood · doi:10.1182/blood-2016-01-678136 · Cited by 70
Considerations in adapting CRISPR/Cas9 in nongenetic model plant systems
Shan, S., Soltis, P. S., Soltis, D. E., & Yang, B. (2020) · Applications in Plant Sciences · doi:10.1002/aps3.11314 · Cited by 71
Wang, L., Yang, Y., Breton, C. A., Bell, P. L., Li, M., Zhang, J., Che, Y., Saveliev, A., He, Z., White, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5701 · Cited by 67
A transient reporter for editing enrichment (TREE) in human cells
Standage-Beier, K., Tekel, S. J., Brookhouser, N., Schwarz, G., Nguyen, T., Wang, X., & Brafman, D. A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz713 · Cited by 66
Genome editing in cardiovascular diseases
Mani, I. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.021 · Cited by 66
State of the art CRISPR-based strategies for cancer diagnostics and treatment
Carlo, E. D., & Sorrentino, C. (2024) · Biomarker Research · doi:10.1186/s40364-024-00701-x · Cited by 69
CRISPR–Cas9-mediated genome editing and guide RNA design
Wiles, M. V., Qin, W., Cheng, A. W., & Wang, H. (2015) · Mammalian Genome · doi:10.1007/s00335-015-9565-z · Cited by 67
Genome editing technologies and their applications in crop improvement
Mishra, R., & Zhao, K. (2018) · Plant Biotechnology Reports · doi:10.1007/s11816-018-0472-0 · Cited by 72
Genome Editing in Mice Using CRISPR/Cas9 Technology
Hall, B., Cho, A., Limaye, A., Cho, K., Khillan, J. S., & Kulkarni, A. B. (2018) · Current Protocols in Cell Biology · doi:10.1002/cpcb.57 · Cited by 72
Hu, Z., Zhang, C., Wang, S., Gao, S., Wei, J., Li, M., Hou, L., Mao, H., Wei, Y., Qi, T., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab148 · Cited by 67
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 66
Sniper2L is a high-fidelity Cas9 variant with high activity
Kim, Y.-H., Kim, N., Okafor, I. C., Choi, S.-C., Min, S., Lee, J., Bae, S.-M., Choi, K., Choi, J., Harihar, V., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01279-5 · Cited by 70
Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy
Yi, K., Kong, H., Lao, Y., Li, D., Mintz, R. L., Fang, T., Chen, G., Tao, Y., Li, M., & Ding, J. (2023) · Advanced Materials · doi:10.1002/adma.202300665 · Cited by 66
Marchetti, F., Cardoso, R., Chen, C. L., Douglas, G. R., Elloway, J. M., Escobar, P. A., Harper, T. A., Heflich, R. H., Kidd, D., Lynch, A. M., et al. (2023) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2023.108466 · Cited by 71
Uemura, T., Mori, T., Kurihara, T., Kawase, S., Koike, R., Satoga, M., Cao, X., Li, X., Yanagawa, T., Sakurai, T., et al. (2016) · Scientific Reports · doi:10.1038/srep35861 · Cited by 65
Scott, T. A., Moyo, B., Nicholson, S., Maepa, M. B., Watashi, K., Ely, A., Weinberg, M. S., & Arbuthnot, P. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-07642-6 · Cited by 66
New considerations for hiPSC-based models of neuropsychiatric disorders
Hoffman, G. E., Schrode, N., Flaherty, E. K., & Brennand, K. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0029-1 · Cited by 71
A versatile reporter system for CRISPR-mediated chromosomal rearrangements
Li, Y., Park, A. I., Mou, H., Colpan, C., Bizhanova, A., Akama‐Garren, E. H., Joshi, N., Hendrickson, E. A., Feldser, D. M., Yin, H., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0680-7 · Cited by 64
The genome editing revolution: A CRISPR‐Cas TALE off‐target story
Stella, S., & Montoya, G. (2016) · BioEssays · doi:10.1002/bies.201670903 · Cited by 66
Scarless Genome Editing of Human Pluripotent Stem Cells via Transient Puromycin Selection
Steyer, B., Bu, Q., Cory, E., Jiang, K., Duong, S., Sinha, D., Steltzer, S. S., Gamm, D. M., Chang, Q., & Saha, K. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.12.004 · Cited by 68
CRISPR-Cas9-based genome-wide screening of Toxoplasma gondii
Sidik, S. M., Huet, D., & Lourido, S. (2018) · Nature Protocols · doi:10.1038/nprot.2017.131 · Cited by 68
Amplification-free long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity
Höijer, I., Johansson, J., Gudmundsson, S., Chin, C.-S., Bunikis, I., Häggqvist, S., Emmanouilidou, A., Wilbe, M., den Hoed, M., Bondeson, M.-L., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02206-w · Cited by 65
Improved design and analysis of CRISPR knockout screens
Chen, C.-H., Xiao, T., Xu, H., Jiang, P., Meyer, C. A., Li, W., Brown, M. A., & Liu, X. S. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty450 · Cited by 63
CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer’s Disease—A Narrative Review
Barman, N. C., Khan, M. N. M., Islam, M., Nain, Z., Roy, R. K., Haque, A., & BARMAN, S. K. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00218-z · Cited by 65
In-depth assessment of the PAM compatibility and editing activities of Cas9 variants
Zhang, W., Yin, J., Zhangding, Z., Xin, C., Liu, M., Wang, Y., Chen, A., & Hu, J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab507 · Cited by 66
Unified energetics analysis unravels SpCas9 cleavage activity for optimal gRNA design
Zhang, D., Hurst, T., Duan, D., & Chen, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820523116 · Cited by 63
Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing
Li, J., Hong, S., Chen, W., Zuo, E., & Yang, H. (2019) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.002 · Cited by 66
Gene Editing and Genotoxicity: Targeting the Off-Targets
Blattner, G., Cavazza, A., Thrasher, A. J., & Turchiano, G. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.613252 · Cited by 64
On- and off-target effects of paired CRISPR-Cas nickase in primary human cells
Klermund, J., Rhiel, M., Köcher, T., Chmielewski, K. O., Bischof, J., Andrieux, G., el Gaz, M., Hainzl, S., Boerries, M., Cornu, T. I., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.006 · Cited by 65
Recent advances in therapeutic gene-editing technologies
Liu, D., Cao, D., & Han, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.026 · Cited by 70
Chen, F., Rosiene, J. A., Che, A., Becker, A. J., & LoTurco, J. J. (2015) · Development · doi:10.1242/dev.118836 · Cited by 62
Tailored Pig Models for Preclinical Efficacy and Safety Testing of Targeted Therapies
Klymiuk, N., Seeliger, F., Bohlooly‐Y, M., Blutke, A., Rudmann, D. G., & Wolf, E. (2015) · Toxicologic Pathology · doi:10.1177/0192623315609688 · Cited by 66
Genome Editing with CRISPR-Cas9: Can It Get Any Better?
Haeussler, M., & Concordet, J. (2016) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.04.008 · Cited by 65
Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9
Singh, K., Evens, H., Nair, N., Rincón, M. Y., Sarcar, S., Samara-Kuko, E., Chuah, M., & VandenDriessche, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.023 · Cited by 63
Benati, D., Miselli, F., Cocchiarella, F., Patrizi, C., Carretero, M., Baldassarri, S., Ammendola, V., Has, C., Colloca, S., Río, M. D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.024 · Cited by 64
Enhancing gene editing specificity by attenuating DNA cleavage kinetics
Miller, J. C., Patil, D. P., Xia, D. F., Paine, C. B., Fauser, F., Richards, H. W., Shivak, D. A., Bendaña, Y. R., Hinkley, S. J., Scarlott, N. A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0186-z · Cited by 63
Lea, R. A., & Niakan, K. K. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0424-0 · Cited by 62
Canaj, H., Hussmann, J. A., Li, H., Beckman, K. A., Goodrich, L., Cho, N. H., Li, Y. J., Santos, D. A., McGeever, A., Stewart, E. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/841098 · Cited by 65
Customizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
Zhang, G., Zeng, T., Dai, Z., & Dai, X. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.03.001 · Cited by 64
Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors
Krishnamurthy, S., Traore, S., Cooney, A. L., Brommel, C. M., Kulhánková, K., Sinn, P. L., Newby, G. A., Liu, D. R., & McCray, P. B. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab788 · Cited by 63
Madison, B., Patil, D. P., Richter, M., Li, X., Tong, M., Cranert, S. A., Wang, X., Martin, R. M., Xi, H., Tan, Y., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.06.003 · Cited by 61
CRISPR nuclease off-target activity and mitigation strategies
Wienert, B., & Cromer, M. K. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.1050507 · Cited by 66
In vivo CRISPR gene editing in patients with herpetic stromal keratitis
Wei, A., Yin, D., Zhai, Z., Ling, S., Le, H., Tian, L., Xu, J., Paludan, S. R., Cai, Y., & Hong, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.021 · Cited by 65
Taemaitree, L., Shivalingam, A., El-Sagheer, A. H., & Brown, T. P. (2019) · Nature Communications · doi:10.1038/s41467-019-09600-4 · Cited by 61
Combinatorial mutagenesis en masse optimizes the genome editing activities of SpCas9
Choi, G. C. G., Zhou, P., Yuen, C. T. L., Chan, B. K. C., Xu, F., Bao, S., Chu, H. Y., Thean, D., Tan, K., Wong, K. H., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0473-0 · Cited by 63
Self-citationCRISPR system: Discovery, development and off-target detection
Chen, S., Yao, Y., Zhang, Y., & Fan, G. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109577 · Cited by 60
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu, E., Luu, M., Alb, M., Anliker, B., Arcangeli, S., Bonini, C., Angelis, B. D., Choudhary, R., Espie, D., Galy, A. H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003486 · Cited by 66
Tracking-seq reveals the heterogeneity of off-target effects in CRISPR–Cas9-mediated genome editing
Zhu, M., Xu, R., Yuan, J., Wang, J., Ren, X., Cong, T., You, Y., Ju, A., Xu, L., Wang, H., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02307-y · Cited by 62
Emerging trends in prime editing for precision genome editing
Lee, J., Kweon, J., & Kim, Y. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01463-8 · Cited by 70
Beyond editing to writing large genomes
Chari, R., & Church, G. M. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.59 · Cited by 60
Sachdeva, M., Busser, B. W., Temburni, S., Jahangiri, B., Gautron, A.-S., Maréchal, A., Juillerat, A., Williams, A., Depil, S., Duchateau, P. N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13088-3 · Cited by 63
Wang, J., Zhang, C., & Feng, B. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15039 · Cited by 61
Cas9 deactivation with photocleavable guide RNAs
Zou, R. S., Liu, Y., Wu, B., & Ha, T. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.007 · Cited by 61
PAM-flexible genome editing with an engineered chimeric Cas9
Zhao, L., Koseki, S. R. T., Silverstein, R. A., Amrani, N., Peng, C., Kramme, C., Savic, N., Pacesa, M., Rodríguez, T. C., Stan, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41829-y · Cited by 59
Wang, L., Breton, C. A., Warzecha, C. C., Bell, P. L., Yan, H., He, Z., White, J., Zhu, Y., Li, M., Buza, E. L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.020 · Cited by 61
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 63
CRISPR-Cas9 for medical genetic screens: applications and future perspectives
Xue, H.-Y., Ji, L.-J., Gao, A.-M., Liu, P., He, J.-D., & Lu, X. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103409 · Cited by 62
Hayes, K. R., Hosack, G. R., Dana, G. V., Foster, S. D., Ford, J. H., Thresher, R., Ickowicz, A., Peel, D. A., Tizard, M. L., Barro, P. D., et al. (2018) · Journal of Responsible Innovation · doi:10.1080/23299460.2017.1415585 · Cited by 59
Lamsfus‐Calle, A., Daniel-Moreno, A., Antony, J. S., Epting, T., Heumos, L., Baskaran, P., Admard, J., Casadei, N., Latifi, N., Siegmund, D. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66309-x · Cited by 61
High-fidelity SaCas9 identified by directional screening in human cells
Xie, H., Ge, X., Yang, F., Wang, B., Li, S., Duan, J., Lv, X., Cheng, C., Song, Z., Liu, C., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000747 · Cited by 59
CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination
Herskovitz, J., Hasan, M., Patel, M., Blomberg, W. R., Cohen, J. D., Machhi, J., Stein, D., Schroder, E. A., McMillan, J., Gurumurthy, C. B., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103678 · Cited by 63
The Role of Recombinant AAV in Precise Genome Editing
Bijlani, S., Pang, K. M., Sivanandam, V., Singh, A., & Chatterjee, S. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.799722 · Cited by 63
Integrating machine learning and genome editing for crop improvement
Chen, L., Liu, G., & Zhang, T. (2024) · aBIOTECH · doi:10.1007/s42994-023-00133-5 · Cited by 60
Engineered natural killer cells for cancer therapy
Biederstädt, A., & Rezvani, K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.013 · Cited by 62
Hu, J. H., Davis, K. M., & Liu, D. R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.12.009 · Cited by 61
Kujoth, G. C., Sullivan, T. D., Merkhofer, R. M., Lee, T.-J., Wang, H., Brandhorst, T. T., Wüthrich, M., & Klein, B. S. (2018) · mBio · doi:10.1128/mbio.00412-18 · Cited by 58
Metadata
- Authors
- Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., Aryee, M. J., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Tsai, Shengdar Q
- Joung, J Keith
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2014-12-16
- Volume
- 33
- Issue
- 2
- Pages
- 187-197
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4320685
- OpenAlex
- W2003797386
- Cited by
- 2,268
- References
- 39
- Citations by year
- 2026: 189 · 2025: 211 · 2024: 196 · 2023: 191 · 2022: 208 · 2021: 211 · 2020: 231 · 2019: 186 · 2018: 187 · 2017: 177 · 2016: 172 · 2015: 105 · 2014: 1
- FWCI
- 62.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM088040, F32GM105189)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR063070)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- GUIDE-seq, CRISPR-Cas nucleases, off-target cleavage, DNA double-strand breaks, genome-wide characterization, genome editing safety
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Cell Line, Humans, Oligodeoxyribonucleotides, Genome, Human, RNA Editing, DNA Breaks, Double-Stranded, High-Throughput Nucleotide Sequencing, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
